KMID : 0032220210330060497
|
|
Annals of Dermatology 2021 Volume.33 No. 6 p.497 ~ p.514
|
|
Consensus Update for Systemic Treatment of Atopic Dermatitis
|
|
Lee Ji-Hyun
Kim Jung-Eun Park Gyeong-Hun Bae Jung-Min Byun Ji-Yeon Shin Min-Kyung Han Tae-Young Hong Seung-Phil Jang Yong-Hyun Kim Hye-One Na Chan-Ho Lew Bark-Lynn Ahn Ji-Young Park Chang-Ook Seo Young-Joon Lee Yang-Won Son Sang-Wook Choi Eung-Ho Park Young-Lip Roh Joo-Young
|
|
Abstract
|
|
|
Background: In 2015, the Korean Atopic Dermatitis Association (KADA) working group published consensus guidelines for treating atopic dermatitis (AD).
Objective: We aimed to provide updated consensus recommendations for systemic treatment of AD in South Korea based on recent evidence and experience.
Methods: We compiled a database of references from relevant systematic reviews and guidelines on the systemic management of AD. Evidence for each statement was graded and classified based on thestrength of the recommendation. Forty-two council members from the KADA participated in three rounds of voting to establish a consensus on expert recommendations.
Results: We do not recommend long-term treatment with systemic steroids forpatients with moderate-to-severe AD due to the risk of adverse effects. We recommend treatment with cyclosporine or dupilumab and selective treatment with methotrexate or azathioprine for patients with moderate-to-severe AD. We suggest treatment with antihistamines as an option for alleviating clinical symptoms of AD. We recommend selective treatment with narrowband ultraviolet B for patients with chronic moderate-to-severe AD. We do not recommend treatment with oral antibiotics for patients with moderate-to-severe AD but who have no signs of infection. We did not reach a consensus on recommendations for treatment with allergen-specific immunotherapy, probiotics, evening primrose oil, orvitamin D for patients with moderate-to-severe AD. We also recommend educational interventions and counselling for patients with AD and caregivers to improve the treatment success rate.
Conclusion: We look forward to implementing a new and updated consensus of systemic therapy in controlling patients with moderate-to-severe AD.
|
|
KEYWORD
|
|
Atopic dermatitis, Consensus, Republic of Korea, Systemic treatment, Therapeutics
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|